175 related articles for article (PubMed ID: 32004536)
1. The Use of Lactose as an Alternative Coating for Nanoparticles.
Betker JL; Anchordoquy TJ
J Pharm Sci; 2020 Apr; 109(4):1573-1580. PubMed ID: 32004536
[TBL] [Abstract][Full Text] [Related]
2. Application of polyglycerol coating to plasmid DNA lipoplex for the evasion of the accelerated blood clearance phenomenon in nucleic acid delivery.
Abu Lila AS; Uehara Y; Ishida T; Kiwada H
J Pharm Sci; 2014 Feb; 103(2):557-66. PubMed ID: 24347396
[TBL] [Abstract][Full Text] [Related]
3. The Effect of Repeat Administration of Lipoplexes on Gene Delivery, Biodistribution, and Cytokine Response in Immunocompetent Tumor-Bearing Mice.
Betker JL; Anchordoquy TJ
J Pharm Sci; 2022 Jul; 111(7):1926-1936. PubMed ID: 34929156
[TBL] [Abstract][Full Text] [Related]
4. Nanoparticle uptake by circulating leukocytes: A major barrier to tumor delivery.
Betker JL; Jones D; Childs CR; Helm KM; Terrell K; Nagel MA; Anchordoquy TJ
J Control Release; 2018 Sep; 286():85-93. PubMed ID: 30030182
[TBL] [Abstract][Full Text] [Related]
5. Improvement of biodistribution and therapeutic index via increase of polyethylene glycol on drug-carrying liposomes in an HT-29/luc xenografted mouse model.
Chow TH; Lin YY; Hwang JJ; Wang HE; Tseng YL; Wang SJ; Liu RS; Lin WJ; Yang CS; Ting G
Anticancer Res; 2009 Jun; 29(6):2111-20. PubMed ID: 19528471
[TBL] [Abstract][Full Text] [Related]
6. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery.
Suk JS; Xu Q; Kim N; Hanes J; Ensign LM
Adv Drug Deliv Rev; 2016 Apr; 99(Pt A):28-51. PubMed ID: 26456916
[TBL] [Abstract][Full Text] [Related]
7. Stealth CD44-targeted hyaluronic acid supramolecular nanoassemblies for doxorubicin delivery: probing the effect of uncovalent pegylation degree on cellular uptake and blood long circulation.
Han X; Li Z; Sun J; Luo C; Li L; Liu Y; Du Y; Qiu S; Ai X; Wu C; Lian H; He Z
J Control Release; 2015 Jan; 197():29-40. PubMed ID: 25449802
[TBL] [Abstract][Full Text] [Related]
8. Impact of PEGylated Nanoparticles on Tumor Targeted Drug Delivery.
Mozar FS; Chowdhury EH
Curr Pharm Des; 2018; 24(28):3283-3296. PubMed ID: 30062957
[TBL] [Abstract][Full Text] [Related]
9. Engineering Well-Characterized PEG-Coated Nanoparticles for Elucidating Biological Barriers to Drug Delivery.
Yang Q; Lai SK
Methods Mol Biol; 2017; 1530():125-137. PubMed ID: 28150200
[TBL] [Abstract][Full Text] [Related]
10. Zwitterionic poly(carboxybetaine)-based cationic liposomes for effective delivery of small interfering RNA therapeutics without accelerated blood clearance phenomenon.
Li Y; Liu R; Shi Y; Zhang Z; Zhang X
Theranostics; 2015; 5(6):583-96. PubMed ID: 25825598
[TBL] [Abstract][Full Text] [Related]
11. Post-pegylated lipoplexes are promising vehicles for gene delivery in RPE cells.
Peeters L; Sanders NN; Jones A; Demeester J; De Smedt SC
J Control Release; 2007 Aug; 121(3):208-17. PubMed ID: 17630013
[TBL] [Abstract][Full Text] [Related]
12. Engineering PEGylated Polyester Nanoparticles to Reduce Complement-Mediated Infusion Reaction.
Maisha N; Naik N; Okesola M; Coombs T; Zilberberg R; Pandala N; Lavik E
Bioconjug Chem; 2021 Oct; 32(10):2154-2166. PubMed ID: 34499487
[TBL] [Abstract][Full Text] [Related]
13. Characterization of long-circulating cationic nanoparticle formulations consisting of a two-stage PEGylation step for the delivery of siRNA in a breast cancer tumor model.
Ho EA; Osooly M; Strutt D; Masin D; Yang Y; Yan H; Bally M
J Pharm Sci; 2013 Jan; 102(1):227-36. PubMed ID: 23132529
[TBL] [Abstract][Full Text] [Related]
14. Anti-PEG antibodies alter the mobility and biodistribution of densely PEGylated nanoparticles in mucus.
Henry CE; Wang YY; Yang Q; Hoang T; Chattopadhyay S; Hoen T; Ensign LM; Nunn KL; Schroeder H; McCallen J; Moench T; Cone R; Roffler SR; Lai SK
Acta Biomater; 2016 Oct; 43():61-70. PubMed ID: 27424083
[TBL] [Abstract][Full Text] [Related]
15. Effect of hyaluronic acid-binding to lipoplexes on intravitreal drug delivery for retinal gene therapy.
Martens TF; Peynshaert K; Nascimento TL; Fattal E; Karlstetter M; Langmann T; Picaud S; Demeester J; De Smedt SC; Remaut K; Braeckmans K
Eur J Pharm Sci; 2017 May; 103():27-35. PubMed ID: 28223236
[TBL] [Abstract][Full Text] [Related]
16. PEGylation for enhancing nanoparticle diffusion in mucus.
Huckaby JT; Lai SK
Adv Drug Deliv Rev; 2018 Jan; 124():125-139. PubMed ID: 28882703
[TBL] [Abstract][Full Text] [Related]
17. Improved intratumoral delivery of PEG-coated siRNA-lipoplexes by combination with metronomic S-1 dosing in a murine solid tumor model.
Tagami T; Abu Lila AS; Matsunaga M; Moriyoshi N; Nakamura H; Nakamura K; Suzuki T; Doi Y; Ishida T; Kiwada H
Drug Deliv Transl Res; 2012 Apr; 2(2):77-86. PubMed ID: 25786716
[TBL] [Abstract][Full Text] [Related]
18. Enhanced colloidal stability and protein resistance of layered double hydroxide nanoparticles with phosphonic acid-terminated PEG coating for drug delivery.
Cao Z; Adnan NNM; Wang G; Rawal A; Shi B; Liu R; Liang K; Zhao L; Gooding JJ; Boyer C; Gu Z
J Colloid Interface Sci; 2018 Jul; 521():242-251. PubMed ID: 29574343
[TBL] [Abstract][Full Text] [Related]
19. Effects of PEG anchors in PEGylated siRNA lipoplexes on in vitro gene‑silencing effects and siRNA biodistribution in mice.
Hattori Y; Tamaki K; Sakasai S; Ozaki KI; Onishi H
Mol Med Rep; 2020 Nov; 22(5):4183-4196. PubMed ID: 33000194
[TBL] [Abstract][Full Text] [Related]
20. PEGylated human serum albumin (HSA) nanoparticles: preparation, characterization and quantification of the PEGylation extent.
Fahrländer E; Schelhaas S; Jacobs AH; Langer K
Nanotechnology; 2015 Apr; 26(14):145103. PubMed ID: 25789544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
